On Nov 13, major Wall Street analysts update their ratings for $Axsome Therapeutics (AXSM.US)$, with price targets ranging from $116 to $150.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and adjusts the target price from $115 to $125.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $106 to $118.
Wells Fargo analyst Cerena Chen maintains with a buy rating, and maintains the target price at $140.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $120 to $125.
Guggenheim analyst Yatin Suneja maintains with a buy rating, and sets the target price at $135.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a third-quarter update, which included surpassing revenue expectations and positive pipeline developments, an analyst has maintained a positive outlook on Axsome Therapeutics. Clarifications regarding the schedule of two concurrent Phase 3 Auvelity ADA trials have delineated the timeline of upcoming catalyst events, with expectations for simultaneous study results in the fourth quarter. It's believed that success in either one of the ADA trials could dispel any lingering concerns over the regulatory outlook for this significant label expansion.
The recent quarter was notably strong for Axsome Therapeutics, chiefly attributed to a promising increase in Auvelity sales. The company remains a top selection due to the belief that its stock possesses the most compelling series of catalysts through the end of the year in the coverage universe.
Here are the latest investment ratings and price targets for $Axsome Therapeutics (AXSM.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月13日，多家華爾街大行更新了$Axsome Therapeutics (AXSM.US)$的評級，目標價介於116美元至150美元。
摩根士丹利分析師Vikram Purohit維持買入評級，並將目標價從115美元上調至125美元。
美銀證券分析師Jason Gerberry維持買入評級，並將目標價從106美元上調至118美元。
富國集團分析師Cerena Chen維持買入評級，維持目標價140美元。
TD Cowen分析師Joseph Thome維持買入評級，並將目標價從120美元上調至125美元。
Guggenheim分析師Yatin Suneja維持買入評級，目標價135美元。
此外，綜合報道，$Axsome Therapeutics (AXSM.US)$近期主要分析師觀點如下：
在第三季度更新後，分析師對axsome therapeutics的前景保持樂觀態度，這次更新包括超過營業收入預期和積極的產品線進展。關於兩項同時進行的第三階段Auvelity ADA試驗的時間表的澄清，已經明確了即將到來的催化事件的時間線，預計在第四季度同時得到研究結果。人們相信，在任一ADA試驗中的成功可以消除對這一重大標籤擴展的監管前景的任何擔憂。
最近一個季度對axsome therapeutics來說特別強勁，主要是由於Auvelity銷售的顯著增長。由於相信其股票在覆蓋範圍內到年底擁有最具吸引力的一系列催化劑，該公司仍然是一個熱門選項。
以下爲今日10位分析師對$Axsome Therapeutics (AXSM.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
